Drugs / Prostaglandin E1
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 41 trial | ||||||
| Phase 4 | NCT00733434 | Jul 2008 → Jul 2009 | thrombotic disease | National Taiwan University Hospital | Unknown | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT00955929 | Aug 2009 → Dec 2020 | erectile dysfunction, penile cancer | Memorial Sloan Kettering Cancer Center | Terminated | No outcome recorded Stop: Enrollment |
| Comparator or background therapy3 trials | ||||||
| Phase 2 | NCT01108120 Comparator | May 2010 → Dec 2022 | ulcer of lower limbs | Xiang Guang-da | Completed | Met primary |
| Phase 2 | NCT00598429 Comparator | May → Sep 2008 | group B streptococcal infection, newborn respiratory distress syndrome, pulmonary hypertension, neonatal | NICHD Neonatal Research Network | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT07503184 Background | Jul 2025 → Jan 2026 | preterm premature rupture of the membranes | Nishtar Medical University | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Prostaglandin E1 | “intravenous injection of prostaglandin E1 20 ug per day during hospitalization period” NCT01108120 ↗ |
| Known as | IPGE1 | “The objective of this study was to evaluate the feasibility of a randomized controlled trial (RCT) of inhaled PGE1 (IPGE1) in NHRF.” PMID 25496504 ↗ Dec 2014 |
| Known as | PGE1 | “intravenous form of Prostaglandin E1 (PGE1)” NCT00598429 ↗ |
| Route | Inhaled | “using the intravenous form of Prostaglandin E1 in an inhaled form” NCT00598429 ↗ |